Inhibition of miR‐155 in MCF‐7 breast cancer cell line by gold nanoparticles functionalized with antagomir and AS1411 aptamer
The DOI matches its Crossref record.
Abstract
MicroRNAs are key factors for many biological functions. These regulatory molecules affect various gene networks and involve the subsequent signaling pathways. Therefore, disrupting the expression of these molecules is associated with multiple anomalies in the cells and body. One of the most important related abnormalities is the incidence of cancer. Thus, targeting microRNAs (miRNAs) is an effective approach for cancer gene therapy. Various factors are used for this purpose, including the antagomir nucleotide structure. There are some obstacles in the delivery of nucleotide therapeutics to the target cells, however, the use of nanoparticles could partly overcome these defeciencies. On the other hand, targeted delivery of antagomirs using aptamers, reduces nonspecific effects on nontarget cells. Considering the above, in this study, we designed and fabricated a nanocarrier composed of gold nanoparticles (GNPs), antagomir‐155, and nucleolin specific aptamer for breast cancer study and therapy. Here, GNPs were synthesized using citrate reduction and were modified by polyA sequences, AS1411 aptamer, and antagomir‐155. Attachment of molecules were confirmed using gel electrophoresis, atomic force microscopy imaging and electrochemical test. The specific entry of modified nanoparticles was investigated by fluorescence microscopy. The efficacy of modified nanoparticles was evaluated using a quantitative polymerase chain reaction (q‐PCR) for miR‐155 and its target gene. Efficient and specific delivery of AuNP–Apt–anti‐miR‐155 to target cells was confirmed in comparison with the control cell. The q‐PCR analysis showed not only a significant decrease in mir‐155 levels but also an elevated TP53INP1 mRNA, direct target of miR‐155. The proposed structure inhibits proliferation and stimulates apoptosis by increasing the expression of TP53INP1. Our results suggest that AuNP–Apt–anti‐miR‐155 could be a promising nano constructor for breast cancer treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Emerging concepts of miRNA therapeutics: from cells to clinic
Diener, C., Keller, A., & Meese, E. (2022) · Trends in Genetics · doi:10.1016/j.tig.2022.02.006 · Cited by 971
Trials and Tribulations of MicroRNA Therapeutics
Seyhan, A. A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25031469 · Cited by 381
“…have also explored other examples of GalNAc-conjugated LNA, anti-miR-122 antisense oligonucleotides, or nano-carrier vehicles in combination with cell type-specific biomolecule conjugates or miR-155 inhibitors by gold nanoparticles formulated with antagomir and AS1411 aptamer [242,243].”
BackgroundAptamer-Functionalized Nanoparticles in Targeted Delivery and Cancer Therapy
Fu, Z., & Xiang, J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21239123 · Cited by 231
MicroRNA as an Important Target for Anticancer Drug Development
Fu, Z., Wang, L., Li, S., Chen, F., Au-Yeung, K. K.-W., & Shi, C. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.736323 · Cited by 133
“Arefeh Kardani et al. reported that an inhibition of miR-155 in MCF-7 breast cancer cell lines was induced by the treatmen of gold nanoparticles functionalized with antagomir-155 (Kardani et al., 2020).”
BackgroundRadiosensitization of breast cancer cells using AS1411 aptamer-conjugated gold nanoparticles
Mehrnia, S. S., Hashemi, B., Mowla, S. J., Nikkhah, M., & Arbabi, A. (2021) · Radiation Oncology · doi:10.1186/s13014-021-01751-3 · Cited by 60
Metadata
- Authors
- Kardani, A., Yaghoobi, H., Alibakhshi, A., & Khatami, M.
- Venue
- Journal of Cellular Physiology
- Publisher
- Wiley
- Published
- 2020-01-31
- Volume
- 235
- Issue
- 10
- Pages
- 6887-6895
- ISSN
- 0021-9541 (ISSN-L)
- 1097-4652
- OpenAlex
- W3003980175
- Cited by
- 65
- References
- 0
- FWCI
- 2.77
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Inhibition of miR‐155 in MCF‐7 breast cancer cell line by gold nanoparticles functionalized with antagomir and AS1411 aptamer. https://app.cochat.ai/papers/10.1002/jcp.29584
- The paper
- Kardani, A., Yaghoobi, H., Alibakhshi, A., & Khatami, M. (2020). Inhibition of miR‐155 in MCF‐7 breast cancer cell line by gold nanoparticles functionalized with antagomir and AS1411 aptamer. Journal of Cellular Physiology. https://doi.org/10.1002/jcp.29584
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.